Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51.
      Google Scholar   
Citation:
Leuk Lymphoma vol 48 (7) 1290-8
Year:
2007
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
CA-15083, CA-25224, CA-35103, CA-35113, CA-35195, CA-35269, CA-35448, CA-37404, CA-52352, CA-60276, CA-63849  
Corr. Author:
 
Authors:
                         
Networks:
 
Study
NCCTG-91-78-51
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Adult, Aged, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Interleukin-4, Lymphoma, Non-Hodgkin, Male, Middle Aged, Recurrence, Salvage Therapy, Survival Analysis, Treatment Outcome